UPDATE: Bloom Burton Cuts PT to $24 on OncoGenex Pharmaceuticals

Bloom Burton lowers its price target on BUy-rated OncoGenex Pharmaceuticals (NASDAQ: OGXI to $24 as the timing of Custirsen approval is pushed back Bloom Burton notes, "Price target decreased to $24.00 from $28.00. This is mainly due to pushing back our timing of custirsen approval for second-line chemotherapy use from 2016 to 2018. We have also rolled forward our valuation by one year." OGXI closed at $15.70 a share on Thursday.